P53 Mutation clinical trials at University of California Health
1 research study open to eligible people
A Study of APG-115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors
open to eligible people ages 12 years and up
Part 1 is the dose escalation of APG-115 in combination with label dose of pembrolizumab. Part 2 is phase II design of APG-115 at recommended phase 2 dose (RP2D) in combination with pembrolizumab.
Our lead scientists for P53 Mutation research studies include Bartosz Chmielowski, MD.